<DOC>
	<DOC>NCT00530335</DOC>
	<brief_summary>The objective is to assess overall safety and tolerability of atomoxetine in doses up to 120 mg/day in Japanese adult patients who meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for ADHD</brief_summary>
	<brief_title>Atomoxetine Phase 2 Study in Japanese Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>at least 18 years of age meet Conners' Adult ADHD Diagnostic Interview for DSMIVâ„¢ (CAADID) diagnostic criteria for current ADHD as well as meeting criteria for a historical diagnosis of ADHD during childhood have a Clinical Global ImpressionADHDSeverity (CGIADHDS) score of 4 (moderate symptoms) or greater Patients who meet DSMIV diagnostic criteria for current major depression and also patients who have total score of more than 12 on the Hamilton Depression Rating Scale17 items (HAMD17) at Visit 1 and Visit 2. Patients who have both a current or past history of major depression and have received any antidepression drug therapy within 6 months of Visit 1. Patients who meet DSMIV diagnostic criteria for have a current anxiety disorder and also require antianxiety drug therapy except for those taking benzodiazepines analogues for anxiety which need to be limited. Patients who have any history of bipolar disorder (DSMIV), any history of schizophrenia or any history of a psychotic disorder (DSMIV) will be excluded from the study. Patients who have been diagnosed (DSMIV) with a pervasive developmental disorder.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>